Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma Publication Population Pharmacokinetics and Exposure-response of Trametinib, a MEK Inhibitor, in Patients with BRAF V600 Mutation-positive Melanoma The purpose of this study was to characterize the pharmacokinetics of oral trametinib, a first in…Certara2016年4月1日
Immune Cell-based Screening Assay for Response to Anticancer Agents: Applications in Pharmacogenomics Publication Immune Cell-based Screening Assay for Response to Anticancer Agents: Applications in Pharmacogenomics Certara2016年2月26日
Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases Publication Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases Certara2016年2月1日
Population PK & Dosing Implications for Cobimetinib in Cancer Patients Publication Population PK & Dosing Implications for Cobimetinib in Cancer Patients A population pharmacokinetic model was developed for cobimetinib in cancer patients. Covariates had minimal impact…Certara2015年11月1日
Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients Publication Modeling & Simulation Relating Survival to Tumor Growth Inhibition in Patients The published OS model and resultant simulations can be leveraged to support Phase II design…Certara2015年9月1日
Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients Publication Population Pharmacokinetic Modeling of Motesanib and Its Active Metabolite, M4, in Cancer Patients Motesanib is a small molecule and potent multikinase inhibitor with antiangiogenic and antitumor activity. Population…Certara2015年7月23日
Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment Publication Population Pharmacokinetic Analysis of Thrombomodulin Alfa to Support Dosing Rationale in Patients with Renal Impairment Thrombomodulin alfa is a soluble recombinant human thrombomodulin that was reported to enhance the reversal…Certara2015年5月1日
Onartuzumab with or without Bevacizumab in Combination with Weekly Paclitaxel Does Not Prolong QTc or Adversely Affect Other ECG Parameters in Patients with Locally Recurrent or Metastatic Triple-negative Breast Cancer Publication Onartuzumab with or without Bevacizumab in Combination with Weekly Paclitaxel Does Not Prolong QTc or Adversely Affect Other ECG Parameters in Patients with Locally Recurrent or Metastatic Triple-negative Breast Cancer The purpose of this study was to examine the potential effect of onartuzumab, when administered…Certara2014年12月17日
Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival Publication Assessment of Tumor Growth Inhibition Metrics to Predict Overall Survival Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size…Certara2014年8月1日
Model-based Meta-analysis for Quantifying Paclitaxel Dose Response in Cancer Patients Publication Model-based Meta-analysis for Quantifying Paclitaxel Dose Response in Cancer Patients Model-based meta-analysis of dose response is a sophisticated method to guide dose and regimen selection.…Certara2014年5月21日